Charles River Laboratories International, Inc. (FRA:RV6)
| Market Cap | 9.35B |
| Revenue (ttm) | 3.44B |
| Net Income (ttm) | -71.39M |
| Shares Out | n/a |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | 20.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1 |
| Open | 184.45 |
| Previous Close | 184.45 |
| Day's Range | 184.45 - 184.45 |
| 52-Week Range | 87.70 - 185.15 |
| Beta | n/a |
| RSI | 76.82 |
| Earnings Date | Feb 18, 2026 |
About FRA:RV6
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o... [Read more]
Financial Performance
In 2024, FRA:RV6's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.
Financial numbers in USD Financial StatementsNews
What Makes Charles River (CRL) a New Buy Stock
Charles River (CRL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue?
Charles River (CRL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons Why You Should Hold Charles River Stock in Your Portfolio
CRAI shares have risen 7% over the past month, with consulting demand lifting its growth outlook and earnings expected to rise in 2026.
Should You Continue to Hold CRL Stock in Your Portfolio for Now?
Charles River gains from strong RMS demand, strategic partnerships and solid finances but faces macro and competitive pressures in 2025.
Charles River (CRL) Receives Upgrade Amid Biopharma Market Changes
Charles River (CRL) Receives Upgrade Amid Biopharma Market Changes
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort an...
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Laun...
What's Driving the Market Sentiment Around Charles River Laboratories International Inc?
Charles River Laboratories International Inc's (NYSE: CRL) short interest as a percent of float has fallen 4.81% since its last report. According to exchange reported data, there are now 2.57 million...
Charles River Laboratories International Inc at Evercore ISI Healthcare Conference Transcript
Charles River Laboratories International Inc at Evercore ISI Healthcare Conference Transcript
Charles River Laboratories (CRL) Stock Declines Amid FDA Announcement
Charles River Laboratories (CRL) Stock Declines Amid FDA Announcement
T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform
BOSTON--(BUSINESS WIRE)--Charles River Development, a State Street Company, announced today the expansion of its relationship with T. Rowe Price through the migration to the SaaS-deployed Charles Rive...
Charles River Laboratories (CRL) Updates on Fourth-Quarter Demand Trends
Charles River Laboratories (CRL) Updates on Fourth-Quarter Demand Trends
HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Dec. 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
Charles River Laboratories to Present at Evercore Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Evercore 8th Annual Healthcare Conference on Wednesday, December 3rd, at 10:00 a.m. ET. Managemen...
Charles River Laboratories to Present at Evercore Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Evercore Healthcare Conference.
Madison Small Cap Fund Q3 2025 Portfolio Activity
The small cap team initiated a new investment position in Hexcel Corporation. Hexcel is a global leader in advanced composite materials. We initiated a position in Charles River Labs in Q3. CRL is a h...
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript
Charles River Laboratories International, Inc. (CRL) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM ESTCompany ParticipantsBirgit...
SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers
STAMFORD, Conn.--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced a new partnership with Charles River Develop...
Charles River Laboratories (CRL) Cleared by SEC After Investigation
Charles River Laboratories (CRL) Cleared by SEC After Investigation
Charles River (CRL) International Revenue Performance Explored
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River (CRL) Clears SEC Inquiry Without Enforcement Action
Charles River (CRL) Clears SEC Inquiry Without Enforcement Action
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Jefferies Global Healthcare Conference.
Wellington Management Group LLP Reduces Stake in Charles River Laboratories International Inc
Wellington Management Group LLP Reduces Stake in Charles River Laboratories International Inc
Charles River (CRL): TD Cowen Lowers Price Target to $197 | CRL Stock News
Charles River (CRL): TD Cowen Lowers Price Target to $197 | CRL Stock News